Nano4Health: life sciences and micro-electronics for novel health solutions

1. Nano4Health: life sciences and micro-
electronics for novel health solutions
Peter Simkens, Managing Director DSP Valley
Henk Joos, Managing Director FlandersBio

2. Content
Page  2
 The perfect storm in health management space
 Innovative Health Solutions: the eye of the storm
 Challenges to bring two worlds together
 Smart Players adapt and collaborate
 Towards a life sciences and technology driven network economy

3. The perfect storm in health management space
Page  3
Unsustainable
healthcare costs
Innovative Health
Solutions
The occurrence of
mega-cities
Consumerism &
digitization
Socio-economic &
behavioral
shifts
Shift from curative
to preventive
Data management
systems
Precision medicine, precision
diagnostics
Social media
Health awareness
and management
Aging global
population
Global travel

4. Innovative Health Solutions: the eye of the storm
Page  4
Pleasure
Pfizer
Abbvie
Abbott
J&J
Roche
Sanofi
Aventis
P&G
Nestle
Samsung
Google
Unilever
Rousselot
Apple
Danone
Novel Health Solutions,
A new mass market driven
by growing risk factors
Insurers are starting to
market directly to
consumers
Medical device and diagnostic
companies are also entering this
space
Source: Winning the Battle for Consumer Healthcare, AT Kearney
Mass ‘Market’
‘Niche
Market’
Consumers
at risk
Patiënts
Roche Diagnostics

5. Challenges bringing Life Sciences and Micro-electronics together
Page  5
 Differences in ‘typical’ product development timelines
 Differences/ Integration in regulatory systems
 Differences in business models
 Value driven vs cost driven
 Differences in financing models and sources
 Differences in language and culture
 We have to train new people with new competence combinations
who can act as translaters
 Smart players adapt and collaborate !!!

6. Smart players adapt and collaborate towards patient
outcomes
Better
Patient
Outcomes
Screening
test
Co Dx
Response
Monitoring
Rx
Data /
Algorithms
wellness
programs
Rx
Screening
Test
Co Dx
Response
Monitoring
Data /
Algorithms
Wellness
programs
Support the drug Integrated solutions to improve outcomes

7. Biocartis and Janssen Collaboration
History
April 2010: JJDC makes initial investment in Biocartis (Series B)
Jan 2011: Janssen signs Collaboration and License Agreement with Biocartis for the
Idylla platform in neurological disease and certain viral infectious diseases
2011 – 2013: Idylla platform and assay development advances and JJDC continues to
participate in funding
2014 – 2015: Adapted the scope of our collaboration with more strategic focus on
companion diagnostics
2015 Idylla Respiratory Viral Panel launch
Idylla EVD = Rapid Ebola Triage Test launch
Several other projects ongoing
7The future of healthcare

8. Biocartis’ Idylla™ Platform
Precision Diagnostics Beyond Simplicity
Ease of use – 2’ hands-on time – minimal training
High level of multiplexing (30+ markers)
Access on demand
Wide range of sample types
Rapid results (35’ to 120’)
Contamination-controlled design
Reliable – Reproducible results
High Sensitivity

9. 1990’s
EARLY 2000’s
2015
• 1/1,000 OF
THE TYPICAL BLOOD
SAMPLE
• MINIMALLY-INVASIVE
GLUCOMETER
• $1000 GENOME
SEQUENCE
• 3-10ML SAMPLE
SIZE
• BUSINESS CARD SIZE
GLUCOMETER
• $1 M GENOME
SEQUENCE
• 10 ML BLOOD
SAMPLE SIZE
• CALCULATORSIZE
GLUCOMETER
EVOLUTION OF
HEALTHCARE TECHNOLOGY
• GENOME
SEQUENCING
NOT POSSIBLE
Samsung and IMEC

10. A Life Science and technology driven network economy
Page  10
FlandersBio
IMECIMinds
VITO
VIB
DSP Valley
Flanders
Make

11. A Life Science and technology driven network economy
Page  11
 The Flanders Life Sciences Hot Spot is in a unique position
to ‘make’ the outcomes of the health management storm
 DSP Valley and FlandersBio as the respective lead clusters in Micro-
electronics and life sciences have decided to join forces to make this happen
 Nano4Health ans XKET4Health (Agentschap Ondernemen)
 Formal MOU signed 10/2015
 We urge the Flanders decision makers to develop together with us the ‘next
stage’ long term vision of a life science and technology driven network
economy.